Advertisement






Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

Right arrow Help viewing high resolution images
Right arrow Return to article

Please click here to obtain permission to reproduce this image.

Click on image to view larger version.



Figure 4 Effects of cerivastatin on p42mapk and p70S6K: In cultured human saphenous vein, SMC PDGF-BB (10 ng/ml, 10 min) markedly stimulated (or phosphorylated) p42mapk as demonstrated by the slower mobility of the enzyme on Western blots. The activation of p42mapk was not inhibited by cerivastatin (10–6 mol/liter), but was markedly reduced by the specific inhibitor of MAPK kinase (MEK), PD98059 (5 x 10–5 mol/liter), while the PI3K inhibitor (wortmannin, 10–5 mol/liter) or the p70S6K inhibitor (rapamycin, 10–5 mol/liter) had no effects on p42mapk activation. The same blots were used for analysis of p70S6K. PDGF-BB stimulated p70S6K activation (or phosphorylation) as demonstrated by the slower mobility of the enzyme on Western blots, which was not influenced by cerivastatin or by PD98095, the specific inhibitor of MEK. In contrast, activation of p70S6K was completely prevented by wortmannin or rapamycin. The results were repeated with three independent experiments.





Right arrow Return to article

 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement